These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1868 related articles for article (PubMed ID: 28201977)

  • 1. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematologic Malignancies: Plasma Cell Disorders.
    Dhodapkar MV; Borrello I; Cohen AD; Stadtmauer EA
    Am Soc Clin Oncol Educ Book; 2017; 37():561-568. PubMed ID: 28561703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.
    Vallet S; Podar K
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S35-53. PubMed ID: 23768134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
    Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
    Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunopathogenesis and immunotherapy of multiple myeloma.
    Tamura H
    Int J Hematol; 2018 Mar; 107(3):278-285. PubMed ID: 29368256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Bone Marrow Microenvironment.
    Moschetta M; Kawano Y; Podar K
    Cancer Treat Res; 2016; 169():63-102. PubMed ID: 27696259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
    Zamagni E; Tacchetti P; Pantani L; Cavo M
    Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic approaches for the treatment of multiple myeloma.
    Rasche L; Weinhold N; Morgan GJ; van Rhee F; Davies FE
    Cancer Treat Rev; 2017 Apr; 55():190-199. PubMed ID: 28431262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
    Lee HC; Weber DM
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD38 as an immunotherapeutic target in multiple myeloma.
    Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F
    Expert Opin Biol Ther; 2018 Dec; 18(12):1209-1221. PubMed ID: 30394809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
    Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
    Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for multiple myeloma.
    Rosenblatt J; Bar-Natan M; Munshi NC; Avigan DE
    Expert Rev Hematol; 2014 Feb; 7(1):91-6. PubMed ID: 24417573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
    Varga C; Laubach JP; Anderson KC; Richardson PG
    Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
    Müller LME; Migneco G; Scott GB; Down J; King S; Askar B; Jennings V; Oyajobi B; Scott K; West E; Ralph C; Samson A; Ilett EJ; Muthana M; Coffey M; Melcher A; Parrish C; Cook G; Lawson M; Errington-Mais F
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel targets for the treatment of relapsing multiple myeloma.
    Giuliani N; Accardi F; Marchica V; Dalla Palma B; Storti P; Toscani D; Vicario E; Malavasi F
    Expert Rev Hematol; 2019 Jul; 12(7):481-496. PubMed ID: 31125526
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.
    Guillerey C; Nakamura K; Vuckovic S; Hill GR; Smyth MJ
    Cell Mol Life Sci; 2016 Apr; 73(8):1569-89. PubMed ID: 26801219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel immunotherapies.
    Yi Q
    Cancer J; 2009; 15(6):502-10. PubMed ID: 20010170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: Immunotherapy in Multiple Myeloma.
    Giuliani N; Malavasi F
    Front Immunol; 2019; 10():1945. PubMed ID: 31475006
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 94.